Krü ppel-like factor 6 (KLF6) belongs to a large family of mammalian Sp1-like/KLF transcription factors that play critical roles in regulating key cellular functions ranging from differentiation to proliferation and apoptosis. [1] [2] [3] [4] [5] KLF6 is an evolutionarily conserved and ubiquitously expressed protein that was originally identified as an activator of pregnancyspecific genes. [6] [7] [8] Initial evidence has implicated KLF6 as a tumor suppressor gene, which was found to be the subject of frequent somatic mutations in certain carcinomas. 9, 10 Given its potential role as a tumor suppressor gene, much effort has gone into determining altered KLF6 genotypes. Results have been rather controversial since a number of studies established that genetic alterations of KLF6 were infrequently observed in distinct types of human cancers (see Lievre et al. 11 and references therein). More significantly, a recent study in mice indicated that targeted inactivation of KLF6 was lethal and severely impaired the proliferation rate of embryonic stem cells. 12 The phenotype observed in KLF6 À/À mice and stem cells strongly suggests that endogenous KLF6 is required for cell cycle progression, thereby contrasting with its potential tumor-suppressive activity. In view of the central role of KLF6 as a key factor in regulating cell growth, we aimed at elucidating the impact of endogenous KLF6 on cell proliferation and apoptosis by successfully applying approaches that employ DNA-damaging drugs and RNA interference. The effects of DNA-damaging agents on cells that undergo cell cycle arrest or apoptosis depending on the extent of the DNA insult, provided a useful experimental system to test whether KLF6 protein levels were modified during these events ( Figure 1a ). Cells were exposed to different concentrations of DNA-damaging agents and cell cycle arrest and apoptosis were determined by BrdU incorporation and caspase 3/7 measurements, respectively. Also, the protein levels of p21 cip1 and p53 were employed to monitor the magnitude of the cellular response to DNA damage. Interestingly, KLF6 protein levels were modified only marginally during cell cycle arrest induced with low doses of DNAdamaging agents (Figure 1a and Supplementary Figure S1 ). In addition, a striking downregulation of KLF6 was found in cells treated with high doses of DNA-damaging drugs that are compatible with apoptosis induction (see below).
The observation that cells maintained KLF6 expression during the cytostatic effect of the DNA-damage response led us to investigate whether KLF6 could be involved in cell cycle control. Therefore, to determine the impact of endogenous KLF6 on cell cycle progression, RNA interference was applied to knock down KLF6 in mammalian cells and the expression of key cell cycle-related proteins together with cell proliferation were analyzed (Figure 1b) . Two KLF6-specific siRNAs were employed that cause a more than 70% reduction of the endogenous KLF6 protein in Cos-7 cells. Notably, the expression levels of the hyperphosphorylated retinoblastoma protein (ppRb) and cyclin D1 were decreased in KLF6-deficient cells, while the cyclin-dependent kinases CDK4, CDK6 and the CDK inhibitor p27 remained unchanged (Figure 1b , left; data not shown). Also, p53 was analyzed and its protein levels or nuclear accumulation was not modified. Downregulation of ppRb and cyclin D1 is interesting since it might reflect that cells are impaired in their proliferation rate. To test this idea, DNA synthesis as an indication of cell cycle progression was determined by BrdU-incorporation assays. Interestingly, specific loss of KLF6 induced cell cycle arrest, while the apoptotic status remained unaffected (Figure 1b Figure S2) . Results clearly showed that KLF6 loss by siRNAs A and B decreased BrdU incorporation, which was also reflected as a reduction of cell numbers in all cell lines analyzed. In conclusion, our results that KLF6 loss induced cell cycle arrest in distinct cell lines position this transcription factor as an important positive regulator of cell proliferation. In light of other reports, our data were rather unexpected since it has been shown that ectopic expression of KLF6 led to cell cycle arrest by increasing p21 cip1 . 9, 13 A possible explanation is that KLF6 might trigger either cell proliferation or cell cycle arrest depending on its protein expression levels, via distinct occupancy of target gene promoters. In addition, KLF6 could also exert its growth promoting activity by regulating other target genes that remain to be identified. Collectively, our data that siRNA-mediated loss of KLF6 led to cell cycle arrest are in full agreement with recent reports demonstrating that KLF6 knockdown impaired cell proliferation in hepatocarcinoma cells 14 and that KLF6 doses of DNA-damaging drugs that are compatible with apoptosis induction (Figure 1a) . Results also revealed a direct association between high levels of stabilized p53 and increased caspase 3/7 activities during the course of the treatment with distinct DNA-damaging drugs ( Figure 1a and Supplementary Figure S1 ). The striking correlation between Time (h) Letters to the Editor p53 stabilization, apoptosis induction and KLF6 reduction led us to investigate whether p53 might be directly involved in KLF6 downregulation. Therefore, p53 and KLF6 protein levels were examined in p53 wild-type (HepG2) or p53 null (Hep3B) cells after treatment with cisplatin ( Figure 1c , left and right, respectively). Similar KLF6 expression kinetics were observed in both cell lines indicating that during cisplatininduced apoptosis, the downregulation of endogenous KLF6 was p53-independent. Our data further indicated that KLF6 downregulation after DNA damage-induced apoptosis was due, at least in part, to decreased levels of its mRNA, which was accompanied by a strong reduction of its promoter activity in a p53-independent manner, while KLF6 protein stability remained unchanged (Figure 1d , left and right, respectively and Supplementary Figure S3) . Interestingly, DNA-damaging agents (cisplatin) and other cytotoxic drugs (flavopiridol) may cause global transcriptional inhibition and this mechanism seems to be relevant in the regulation of short-lived proteins like p21 cip1 , MDM2 and also KLF6 (Vichi et al. 15 and Demidenko et al. 16 ; Supplementary Figure S3 ). Downregulation of KLF6 upon DNA damage has been previously described. 17, 18 However, the potential impact of KLF6 on apoptosis regulation has not yet been analyzed and so far this is the first report indicating that endogenous KLF6 might play a role in the underlying mechanisms of apoptosis triggered by DNA-damaging drugs. To further explore this possibility, we set out to efficiently knock down endogenous KLF6 in HepG2 cells where apoptosis was induced by DNA damage in a particular time frame as determined by caspase 3/7 activities (Figure 1e, top) . Interestingly, KLF6 loss sensitized HepG2 cells to cisplatin-induced apoptosis in a time-dependent manner, indicating an antiapoptotic function for endogenous KLF6. To extend these results, a similar KLF6 knockdown experiment was conducted and DNA fragmentation indicative of cell death was analyzed by flow cytometry and TUNEL assays (Figure 1e, bottom and f, respectively) . Significantly, these data clearly demonstrated that KLF6 loss by siRNAs increased the sub-G 1 apoptotic cell population, which in turn correlated directly with nuclear DNA fragmentation. In addition, controlled overexpression of KLF6 protected HeLa cells from cisplatin-induced apoptosis (Supplementary information, Supplementary Figure S4 ).
At this stage of analysis, it is most likely that KLF6 is operating as an antiapoptotic factor, yet further studies are necessary to determine how KLF6 exerts its activity on apoptosis regulation. Also, in this context, it was recently reported that KLF6 protects hepatocellular carcinoma-derived cells from apoptosis in vitro, thus highlighting the potential role of KLF6 as an antiapoptotic factor. 14 Taken together, our results are interesting for several reasons: (i) the role of KLF6 as a positive regulator of cell cycle progression and also as an antiapoptotic factor may have a significant impact in determining cell numbers in mammals since KLF6 is a ubiquitous factor that is expressed early during development and in adult tissues. Recently, we and others have found that yet another protein from the mitochondrial carrier family, the inorganic phosphate carrier (PiC), may participate in the regulation of mitochondrial membrane permeabilization. A genome-wide cDNA screen identified PiC as one of the few proteins that, if overexpressed, is able to efficiently trigger the intrinsic pathway of apoptosis. 7 PiC was also found to functionally interact with the cytomegalovirus (CMV)-encoded protein vMIA (i.e. viral mitochondrial inhibitor of apoptosis). 8, 9 vMIA inhibits apoptosis by recruiting Bax to mitochondria, thereby provoking its inactivation. 10, 11 In addition, vMIA is responsible for the early cytopathic effect associated with CMV infection, 8 independently from its interaction with Bax. 8, 12 Moreover, vMIA inhibits the PiC-mediated transport of inorganic phosphate across the inner mitochondrial membrane, thereby reducing ATP synthesis (which is strictly dependent on phosphate import). In turn, this results in a disorganization of the actin cytoskeleton and rounding up of the cells, which characterize the CMV-mediated early cytopathic effect. 8 We have recently reported that, similar to Bax, vMIA can stimulate the fragmentation of the mitochondrial network. 13 This is intriguing and counterintuitive because vMIA is a strong inhibitor of apoptosis, 9 while mitochondrial fragmentation is often associated with apoptosis induction.
14 Since vMIA-mediated mitochondrial fragmentation occurs even in Bax-depleted cells, 8 this effect must be independent of the vMIA-mediated recruitment of Bax to the outer mitochondrial membrane. We therefore sought whether the depletion of PiC with two distinct small interfering RNAs (siRNAs) (Figure 1a ; Supplementary Materials and Methods) might affect the 
Macrofragm. Normal
(a trigger for the extrinsic apoptotic pathway), even when PiC was depleted (Figure 1c) . Hence, PiC is required for the mitochondrial fragmentation caused by vMIA, yet has no role in vMIA-mediated apoptosis inhibition. These data underline the notion that mitochondrial fragmentation and initiation of the mitochondrial pathway of apoptosis do not correlate in an obligatory fashion. 13, 15 This holds true also at a molecular level, as recently demonstrated for the protein hFis1. 16 Notably, hFis1 (that normally promotes both apoptosis and mitochondrial fragmentation) loses selectively its lethal effects (not the ability to fragment mitochondria) in cells lacking the proapoptotic modulators Bax and Bak, or upon different mutations in the intermembrane region. 16 Next, we investigated whether the contribution of PiC to mitochondrial fragmentation would be restricted to this particular system of fragmentation (i.e. that stimulated by vMIA) or whether PiC might play a general role in this process. Mitofusin 2 (Mfn-2) is a GTPase required for mitochondrial fusion the absence which has been previously shown to promote mitochondrial fragmentation. 17 HeLa Neo cells transfected with an irrelevant siRNA exhibited a multibranched, reticular mitochondrial network (Figure 1d, panel  1) . On the contrary, mitochondria from cells depleted for Mfn-2 appeared either with a finely punctuated perinuclear pattern (microfragmentation; Figure 1d , panel 2) or as large dots dispersed throughout the cytoplasm (macrofragmentation; Figure 1d , panel 3). Again, this effect was abolished by the simultaneous knockdown of PiC, which still failed to affect mitochondrial morphology per se ( Figure 1d, panel 4 ; Figure 1e ). The same effect was observed also in a nonsmall cell lung cancer cell line (A549), which exhibited only macro-(and not micro-) fragmented mitochondria following the knockdown of Mfn-2 (Supplementary Figure 1) . Hence, PiC may play a rather general role in mitochondrial dynamics. At this point, the exact mechanism by which PiC participates in mitochondrial fragmentation is unknown. Although it appears plausible that mitochondrial fission requires PiC at some point, it remains to be established whether PiC directly contributes to the fission machinery at the inner mitochondrial membrane, or whether the metabolic alterations induced by PiC depletion (and a consequent phosphate deficiency within the mitochondrial matrix) indirectly impact on the equilibrium of fusion and fission events. Previous reports indicate that changes in energy substrate availability induce deep structural modifications of the mitochondrial network, aimed to accommodate increased amount of the respiratory chain components. 18 In this regard, PiC downregulation might (at least theoretically) counteract mitochondrial fragmentation via a similar effect, yet it seems very improbable that the lack of PiC would favor, instead of inhibiting (by limiting the availability of inorganic phosphate for ATP synthesis), oxidative phosphorylation. 18 Irrespective of these unresolved issues, it appears clear that PiC can profoundly influence mitochondrial dynamics. Although there is overwhelming correlative evidence, in several species, that mitochondrial fragmentation correlates with mitochondrial outer membrane permeabilization, 19 the present report illustrates that this correlation is not absolute. Thus, the antiapoptotic protein vMIA induces mitochondrial fragmentation in a process that is clearly unrelated to its apoptosis-regulatory function.
